PIMAVANSERIN Drug Patent Profile

« Back to Dashboard

Which patents cover Pimavanserin, and when can generic versions of Pimavanserin launch?

Pimavanserin is a drug marketed by MSN and Zydus and is included in three NDAs.

The generic ingredient in PIMAVANSERIN is pimavanserin tartrate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the pimavanserin tartrate profile page.

Summary for PIMAVANSERIN

US Patents:	0
Applicants:	2
NDAs:	3
Clinical Trials:	42
Patent Applications:	1,020
DailyMed Link:	PIMAVANSERIN at DailyMed

Recent Clinical Trials for PIMAVANSERIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Icahn School of Medicine at Mount Sinai	PHASE2
University of Oxford	NA
University of Kansas Medical Center	Phase 2

See all PIMAVANSERIN clinical trials

Pharmacology for PIMAVANSERIN

Drug Class

Atypical Antipsychotic

US Patents and Regulatory Information for PIMAVANSERIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msn	PIMAVANSERIN	pimavanserin tartrate	CAPSULE;ORAL	214925-001	Jan 16, 2024		DISCN	No	No
Zydus	PIMAVANSERIN	pimavanserin tartrate	CAPSULE;ORAL	214493-001	Jan 16, 2024		DISCN	No	No
Zydus	PIMAVANSERIN	pimavanserin tartrate	TABLET;ORAL	214502-001	Jan 16, 2024		DISCN	No	No

Pimavanserin Market Dynamics and Financial Trajectory

Last updated: October 28, 2026

Pimavanserin, marketed by Acadia Pharmaceuticals as Nuplazid, is a selective serotonin 5-HT2A inverse agonist approved in the United States for hallucinations and delusions associated with Parkinson’s disease psychosis. The product remains Acadia’s core commercial asset, although its contribution to company growth is declining as Daybue, the company’s trofinetide product for Rett syndrome, expands.

Nuplazid generated approximately $600 million in annual U.S. net sales in 2024, based on Acadia’s reported product performance and company revenue disclosures. Its growth profile has shifted from rapid market penetration to a mature specialty-pharmaceutical franchise exposed to label restrictions, payer controls, generic entry risk, and limited approved indications. The primary value drivers are continued retention in Parkinson’s disease psychosis, successful expansion into additional psychosis populations, and the timing of generic competition.

What is pimavanserin approved to treat?

Pimavanserin is approved under the brand name Nuplazid for hallucinations and delusions associated with Parkinson’s disease psychosis in adults. The FDA approved the drug in April 2016 through the 505(b)(1) pathway, granting Acadia an orphan-drug-based commercial opportunity in a population with limited approved pharmacologic options.[1]

The approved dosage is 34 mg once daily, administered as two 17 mg tablets or one 34 mg capsule, depending on the marketed presentation. Pimavanserin does not have dopamine D2 receptor antagonism, which differentiates it from conventional antipsychotics and supports its use in Parkinson’s disease, where dopamine blockade can worsen motor symptoms.[2]

Attribute	Pimavanserin / Nuplazid
Active ingredient	Pimavanserin tartrate
Pharmacologic class	5-HT2A inverse agonist and antagonist
Initial U.S. approval	April 29, 2016
Approved indication	Parkinson’s disease psychosis
Primary commercial company	Acadia Pharmaceuticals
Standard adult dose	34 mg once daily
U.S. regulatory status	FDA approved
Product type	Small-molecule prescription drug
Main commercial market	U.S. specialty neurology and psychiatry

The label carries the FDA class warning that elderly patients with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death. Nuplazid is not approved for the treatment of patients with dementia-related psychosis unless the psychosis is related to Parkinson’s disease.[2]

How large is the pimavanserin market?

The commercial market is concentrated in the United States because Nuplazid has historically generated nearly all of its product revenue from U.S. sales. Acadia’s commercial infrastructure, reimbursement relationships, and physician awareness are centered on movement-disorder neurologists, psychiatrists, and long-term-care prescribers.

The addressable Parkinson’s disease psychosis population is materially larger than the treated population, but diagnosis and treatment rates remain constrained by several factors:

• Psychosis may be intermittent or underreported.
• Physicians may reduce or discontinue Parkinson’s disease medications before prescribing an antipsychotic.
• Caregivers may delay treatment because of sedation, falls, or mortality concerns.
• Reimbursement varies across Medicare Part D, Medicare Advantage, Medicaid, and commercial plans.
• Some clinicians continue to use off-label quetiapine or clozapine despite their limitations.

Parkinson’s disease psychosis commonly develops later in the disease course and affects a meaningful minority of patients. Published estimates vary widely because studies use different diagnostic criteria and patient populations.[3] The market therefore has substantial clinical need but a narrower commercially accessible population.

What is the competitive landscape for pimavanserin?

Nuplazid competes with off-label therapies rather than with another FDA-approved drug specifically labeled for Parkinson’s disease psychosis in the United States.

Therapy	U.S. status in Parkinson’s disease psychosis	Commercial implication
Pimavanserin	FDA approved	Premium branded product with label-specific evidence
Quetiapine	Off-label	Low-cost, widely used, weak controlled-trial evidence
Clozapine	Off-label	Evidence-supported but requires blood monitoring
Risperidone	Off-label	Dopamine blockade can worsen motor symptoms
Olanzapine	Off-label	Motor and metabolic adverse-effect concerns
Lumateperone	Not approved for Parkinson’s disease psychosis	Potential future competitor only if development succeeds

Pimavanserin’s principal advantage is the absence of direct dopamine receptor blockade. Its principal commercial weakness is price relative to generic off-label antipsychotics.

How has Acadia’s pimavanserin revenue changed?

Nuplazid became Acadia’s first major commercial product and funded the company’s transition from development-stage biotechnology company to specialty pharmaceutical company. Sales grew rapidly after the 2016 launch, supported by the absence of an FDA-approved direct competitor and increasing physician familiarity.

Public filings indicate the following broad financial trajectory:

Period	Commercial development	Financial interpretation
2016-2017	Initial launch and market access expansion	Rapid prescription growth from a low base
2018-2020	Expansion in diagnosed Parkinson’s disease psychosis	Nuplazid became Acadia’s principal revenue source
2021	Continued sales growth but greater regulatory scrutiny	Label-risk and safety concerns increased investor sensitivity
2022-2023	Mature branded-product growth	Revenue remained dependent on U.S. Parkinson’s disease psychosis
2024 onward	Daybue became a second major franchise	Pimavanserin remained important but less dominant in company valuation

Acadia reported total revenue of approximately $603.9 million in 2023, with Nuplazid accounting for the majority of product sales before Daybue’s commercial contribution became material.[4] In 2024, Acadia’s total revenue increased substantially as Daybue sales expanded. That growth reduced the company’s dependence on pimavanserin even though Nuplazid remained a large revenue contributor.[5]

The financial trajectory has three phases:

1. Launch growth driven by new patient starts.
2. Mature growth driven by persistence, price increases, and greater treatment penetration.
3. Portfolio diversification driven by Daybue, with Nuplazid becoming a cash-generating but slower-growth product.

What are the main revenue drivers for Nuplazid?

Nuplazid revenue is driven by net price, treated patient volume, refill persistence, payer access, and the ability to expand into additional approved indications.

Patient volume

The Parkinson’s disease psychosis population grows slowly because it is tied to the prevalence and aging profile of Parkinson’s disease. New patient growth is therefore more dependent on diagnosis and treatment penetration than on rapid disease-market expansion.

Treatment persistence

Patients who remain on therapy generate recurring revenue. Persistence can be affected by adverse events, perceived lack of efficacy, disease progression, caregiver decisions, and insurance coverage changes.

Net price

Acadia has historically used specialty-pharmaceutical pricing rather than generic-equivalent pricing. Net price growth can offset modest prescription growth, but aggressive price increases may increase payer restrictions and political scrutiny.

Payer mix

Medicare is economically important because Parkinson’s disease psychosis disproportionately affects older adults. Coverage under Medicare Part D can expose patients to deductibles and coinsurance, while specialty-tier placement can affect initiation and persistence.

Indication expansion

An approved indication in dementia-related psychosis could materially expand the market, but the regulatory and safety risks are substantial. A successful schizophrenia program could also increase the addressable market, although development and commercial competition would be more intense.

What happened to pimavanserin’s dementia-related psychosis program?

Acadia sought to expand pimavanserin into dementia-related psychosis, a market considerably larger than Parkinson’s disease psychosis. In 2020, the FDA issued a Complete Response Letter for the supplemental application covering hallucinations and delusions associated with dementia-related psychosis.[6]

The FDA later accepted a resubmission, and Acadia received approval in April 2023 for Nuplazid in hallucinations and delusions associated with Parkinson’s disease psychosis only. The company did not receive a broad dementia-related psychosis approval.[7]

This outcome materially limited the near-term market opportunity. Dementia-related psychosis remains commercially attractive, but the product cannot be promoted broadly for that population without an applicable FDA approval. Off-label use is legally and commercially constrained, particularly for a product with a boxed warning concerning mortality in elderly patients with dementia-related psychosis.

Could schizophrenia expand the pimavanserin market?

Schizophrenia represents a larger potential market than Parkinson’s disease psychosis, but the competitive and clinical requirements are higher. Acadia studied pimavanserin as an adjunctive treatment for schizophrenia symptoms, including negative symptoms and inadequate response to antipsychotics.

A prior Phase 3 study in schizophrenia did not meet its primary endpoint, weakening the near-term expansion case.[8] Pimavanserin would also face established generic antipsychotics, newer branded agents, long-acting injectables, and combination products.

The schizophrenia opportunity has commercial value only if pimavanserin demonstrates a clinically differentiated benefit without materially increasing adverse events. A successful adjunctive indication could support substantial revenue, but the development history makes that outcome uncertain.

What patents protect pimavanserin and Nuplazid?

Nuplazid’s U.S. protection is based on a combination of composition, formulation, dosage, and method-of-use patents. The earliest core compound protection is less important commercially than later patents covering the marketed product and approved use.

Public patent and regulatory records identify several relevant patent categories:

Patent category	Scope	Commercial role
Compound patents	Pimavanserin chemical entity and salts	Foundational protection
Formulation patents	Oral dosage forms and pharmaceutical compositions	Protect marketed presentations
Method-of-use patents	Treatment of psychosis, including Parkinson’s disease psychosis	Supports Orange Book strategy
Dosing patents	Administration regimens and strengths	May narrow generic design-around options
Manufacturing patents	Processes, intermediates, and impurity control	Can increase technical barriers

Exact enforceability depends on claim scope, terminal disclaimers, patent-term adjustment, prosecution history, and Paragraph IV litigation outcomes. Patent expiration dates should be evaluated patent by patent rather than by relying on a single “Nuplazid patent expiration” date.

Acadia’s protection strategy has commercial importance because a generic applicant may challenge only selected Orange Book-listed patents. A generic can potentially launch after successfully invalidating or avoiding the asserted patents even if other non-Orange-Book intellectual property remains in force.

What is the Orange Book and Paragraph IV status of Nuplazid?

Nuplazid’s Orange Book position is central to generic-entry timing. An ANDA applicant can file a Paragraph IV certification alleging that an Orange Book-listed patent is invalid, unenforceable, or not infringed. Acadia can then sue within the statutory period, triggering a 30-month stay of FDA approval in many circumstances under the Hatch-Waxman framework.[9]

The principal commercial questions are:

• Which Nuplazid patents are listed in the Orange Book?
• Which patents are certified against by each ANDA applicant?
• Whether Acadia files timely infringement actions.
• Whether the case ends in settlement, judgment, or dismissal.
• Whether the generic applicant receives a first-filer exclusivity period.
• Whether a court finds the asserted patents valid and infringed.

Public company filings have disclosed generic litigation and ANDA activity affecting Nuplazid. The risk is not binary. Multiple applicants can create staggered entry dates, and a settlement with one applicant does not necessarily eliminate the risk from other applicants.

When could generic pimavanserin enter the U.S. market?

The likely generic-entry window depends on the surviving patent estate, litigation outcomes, regulatory approval, and any settlement agreements. A generic may enter before the latest listed patent expiration if it wins a validity or infringement dispute, receives a license, or launches at risk.

Generic entry scenarios include:

Scenario	Market effect
No approved ANDA before key patent expiry	Continued branded monopoly
Single generic launch	Moderate price erosion and prescription migration
Multiple generic launches	Rapid net-price compression
Authorized generic or settlement launch	Controlled erosion before full patent expiry
At-risk launch	Potential abrupt share loss followed by litigation damages exposure
Formulation or dosage challenge	Partial competition if the generic avoids selected claims

For a mature oral small molecule, U.S. net sales can fall sharply after multiple generic entrants. The decline is usually faster when payers substitute automatically and when the product has no complex delivery system or biologic manufacturing barrier.

How strong is the pimavanserin patent estate?

The estate is commercially meaningful but structurally less durable than a biologic or a product protected by a complex device. Pimavanserin is an oral small molecule, and generic manufacturers may have several potential routes to challenge patents.

Strengths include:

• FDA-approved use in a defined, underserved population.
• Method-of-use protection that may complicate labeling strategies.
• Multiple patent categories rather than a single compound patent.
• Established commercial demand that justifies generic litigation.
• Potential formulation and dosage claims.

Weaknesses include:

• A small-molecule active ingredient with conventional oral delivery.
• Substitution pressure from low-cost off-label antipsychotics.
• The possibility of Paragraph IV challenges.
• Limited international revenue diversification.
• A market in which payer substitution can be rapid after generic approval.

Manufacturing patents may have less practical value than formulation or method-of-use patents unless they cover difficult-to-reproduce intermediates, impurity profiles, or economically important production steps.

What regulatory risks affect pimavanserin?

The FDA has scrutinized pimavanserin because of adverse-event reports, use in vulnerable elderly populations, and the product’s relationship to dementia-related psychosis. In 2018, the FDA reviewed the product’s safety profile following public concerns and did not request withdrawal from the market.[10]

Key regulatory risks are:

• Expansion of use beyond the approved Parkinson’s disease psychosis population.
• Mortality and cardiac safety concerns associated with antipsychotic-class warnings.
• Off-label use in dementia-related psychosis.
• Postmarketing safety findings.
• Promotional or promotional-practice violations.
• Clinical-trial failures in broader indications.

The FDA’s decision not to withdraw Nuplazid reduced immediate product risk, but safety remains a valuation variable because the treated population is elderly, medically complex, and vulnerable to hospitalization and mortality events.

Which companies challenge or compete with pimavanserin?

The most important competitive threats are generic manufacturers and off-label prescribers rather than branded direct competitors.

Potential generic competitors include companies that file ANDAs for pimavanserin tablets or capsules. Their commercial impact depends on approval timing, Paragraph IV certification, settlement terms, and the number of approved applicants.

Clinical competitors include:

• Generic quetiapine.
• Generic clozapine.
• Generic risperidone.
• Generic olanzapine.
• Emerging branded antipsychotics seeking broader neurologic or psychiatric indications.

Acadia’s internal competition also matters. Daybue has become the company’s major growth asset, shifting management attention and investor valuation away from a single-product model.[5]

How does pimavanserin compare with Daybue in Acadia’s portfolio?

Measure	Nuplazid	Daybue
Active ingredient	Pimavanserin	Trofinetide
Initial U.S. approval	2016	2023
Disease area	Parkinson’s disease psychosis	Rett syndrome
Commercial maturity	Mature	Growth-stage
Primary risk	Generic entry and label limitations	Launch execution, safety, reimbursement
Market type	Specialty neurology and psychiatry	Rare disease
Revenue role	Cash-generating base	Principal growth driver
IP profile	Small-molecule patent and Hatch-Waxman risk	Rare-disease exclusivity and patent protection

Nuplazid provides recurring revenue and commercial infrastructure. Daybue offers greater near-term growth potential but carries launch and market-access execution risk. The portfolio combination improves Acadia’s financial resilience because the company is less dependent on one product’s patent life.

What are the major financial risks for pimavanserin investors?

The main risks are:

1. Generic launch before the market expects it.
2. Accelerated price erosion after multiple ANDA approvals.
3. Slower prescription growth in Parkinson’s disease psychosis.
4. Failure to obtain a broader psychosis indication.
5. Safety-related prescribing restrictions.
6. Medicare and payer pressure on net price.
7. Reduced corporate focus as Daybue becomes the larger growth asset.
8. Litigation costs and potential settlement payments.

Revenue concentration remains important even after Daybue’s launch. A sharp Nuplazid decline would reduce cash generation, operating leverage, and Acadia’s ability to fund pipeline development.

Key Takeaways

• Pimavanserin is marketed as Nuplazid and is FDA approved for hallucinations and delusions associated with Parkinson’s disease psychosis.
• The product generated roughly $600 million in annual U.S. sales around 2024 and remains a major Acadia revenue source.
• Nuplazid has moved from rapid-growth launch product to mature specialty-pharmaceutical franchise.
• The broader dementia-related psychosis opportunity has not produced a broad FDA approval.
• Schizophrenia expansion remains commercially attractive but clinically unproven.
• Generic entry is the largest long-term financial risk.
• Orange Book patents, Paragraph IV litigation, and settlement terms determine the practical exclusivity period.
• Daybue has reduced Acadia’s dependence on pimavanserin and is now the company’s principal growth driver.
• The patent estate has value but is less structurally durable than protection for biologics or complex delivery systems.
• Long-term Nuplazid value depends on persistence in Parkinson’s disease psychosis, pricing, payer access, and the timing of generic competition.

Frequently Asked Questions

Is pimavanserin a first-line treatment for Parkinson’s disease psychosis?

Pimavanserin is an FDA-approved treatment option, but treatment sequencing depends on symptom severity, medication changes, comorbidities, fall risk, cognition, and physician judgment.

Does pimavanserin worsen Parkinson’s motor symptoms?

Pimavanserin does not directly block dopamine D2 receptors, which reduces the pharmacologic basis for worsening motor symptoms compared with dopamine-blocking antipsychotics. Individual patients can still experience adverse events.

Is Nuplazid approved for Alzheimer’s disease psychosis?

No. Nuplazid is not broadly approved for Alzheimer’s disease psychosis or dementia-related psychosis.

Can generic pimavanserin be substituted automatically?

Automatic substitution depends on FDA approval, the specific dosage form, state pharmacy law, payer policy, and whether the generic is therapeutically equivalent to the branded product.

What would most increase pimavanserin’s value?

The largest potential value increase would come from a successful, FDA-approved expansion into a larger psychosis population combined with durable patent protection and continued safety acceptance.

References

1. U.S. Food and Drug Administration. (2016). FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease.
2. U.S. Food and Drug Administration. (2024). Nuplazid (pimavanserin) prescribing information. Acadia Pharmaceuticals, Inc.
3. Ffytche, D. H., Creese, B., Politis, M., Chaudhuri, K. R., Weintraub, D., Ballard, C., & Aarsland, D. (2017). The psychosis spectrum in Parkinson disease. Nature Reviews Neurology, 13(2), 81-95.
4. Acadia Pharmaceuticals, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023.
5. Acadia Pharmaceuticals, Inc. (2025). Annual report on Form 10-K for the fiscal year ended December 31, 2024.
6. U.S. Food and Drug Administration. (2020). Complete response letter for Nuplazid supplemental new drug application.
7. U.S. Food and Drug Administration. (2023). Nuplazid supplemental approval and prescribing information.
8. Acadia Pharmaceuticals, Inc. (2020). Pimavanserin schizophrenia clinical-trial disclosures.
9. U.S. Food and Drug Administration. (2024). Hatch-Waxman Amendments and abbreviated new drug application patent certifications.
10. U.S. Food and Drug Administration. (2018). FDA analysis of postmarketing adverse events associated with Nuplazid.